Bio
Todd Wills is a Managing Director in the CAS Services group. He is responsible for shaping the vision and setting the strategic direction for the Custom Services business. Prior to joining CAS, he worked at Emerson Electric where he served in a variety of corporate and operating roles, most recently running their global, data-driven battery monitoring and diagnostics business. Todd holds an MBA from The Ohio State University and a BS in Finance from John Carroll University.
Drug Discovery
Breakthrough therapy designation: The real-world impact of structural novelty
Find out how companies improve their prediction accuracy, obtain Breakthrough Technology Status and shorten the development and review time of new drugs by leveraging CAS advanced machine learning methods.
Drug Discovery
AI drug discovery: assessing the first AI-designed drug candidates to go into human clinical trials
This blog details the recently published CAS indicator of drug innovation based on the structural novelty of new molecular entities (NMEs) which may better assess innovativeness of new drugs.